In combination with the TLR4 agonist, the circGPC3 vaccine effectively suppressed tumor progression in subcutaneous and orthotopic tumor mouse models, and showed a favorable safety profile with no apparent evidence of tissue damage (62). This evidence concerns the gene TLR4 and neoplasm.